Recommended changes to oncology clinical trial design: Revolution or evolution?

Randomized phase II clinical trials.

Richard Simon, R. Wittes, Susan S. Ellenberg · PubMed · 1985 · 470 citations

Public Health, Biostatistics, Pharmacology +17

Design Issues of Randomized Phase II Trials and a Proposal for Phase II Screening Trials

Edward L. Korn, Boris Freidlin, Sally Hunsberger et al. · Journal of Clinical Oncology · 2005 · 410 citations

Medicine, Oncology, Comparative Effectiveness Research +16

Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non Small-Cell Lung Cancer

Theodore Karrison, Michael L. Maitland, Walter M. Stadler et al. · JNCI Journal of the National Cancer Institute · 2007 · 176 citations · Full text

Medicine, Oncology, Pharmacology +16

Verteporfin Therapy and Intravitreal Bevacizumab Combined and Alone in Choroidal Neovascularization due to Age-Related Macular Degeneration

Ratimir Lazić, Nikica Gabrić · Ophthalmology · 2007 · 127 citations

Medicine, Oncology, Ophthalmology +17

Endpoints and other considerations in phase I studies of targeted anticancer therapy: Recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT)

Christopher M. Booth, A. Hilary Calvert, Giuseppe Giaccone et al. · European Journal of Cancer · 2007 · 109 citations

Medicine, Oncology, Cancer Pharmacology +15